<DOC>
	<DOCNO>NCT01299701</DOCNO>
	<brief_summary>This study design characterize absorption , distribution , metabolism excretion ( ADME ) ASA404 follow single intravenous administration 3000 mg ( approximately 1800 mg/m2 ) ASA404 contain 60 µCi 14C period 20 minute patient advance solid tumor . Metabolic pathways , route ( ) elimination , distribution characteristic plasma blood , exposure characterization plasma blood , exposure characterization parent drug metabolite obtain study .</brief_summary>
	<brief_title>A Single Center Study Characterize Absorption , Distribution , Metabolism Excretion ( ADME ) ASA404 After Single Infusion Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Vadimezan</mesh_term>
	<criteria>Histologically proven diagnosis advance metastatic solid tumor either refractory standard therapy exist , treatment investigational agent alone combination docetaxel , paclitaxel , carboplatin , paclitaxel plus carboplatin appropriate ; ANC≥ 1.5 x 109/L ; Hgb ≥ 9.0 g/L ; PLT ≥ 100,000/mm3 ; Total bilirubin ≤ 1.5 ; Willing able remain clinic least 4 day Patients CNS and/or leptomeningeal disease metastasis allow study unless asymptomatic require corticosteroid therapy . Patients clinical sign CNS metastases must CT MRI brain perform rule CNS metastasis order eligible study participation . Patients brain metastasis surgically remove irradiated residual disease confirm imaging allow ; Patients unable undergo intravenous infusion ; Patients Baseline 12lead EGC QTc &gt; 450 msec ; Radiotherapy le two ( 2 ) week prior study entry ; A history noncompliance medical regimen inability unwillingness return schedule visit Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced metastatic cancer</keyword>
	<keyword>refractory</keyword>
	<keyword>core phase</keyword>
	<keyword>extension phase</keyword>
	<keyword>dose escalation</keyword>
	<keyword>standard chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
</DOC>